- Home
- BTX vs SUPN Comparison
BTX vs SUPN Comparison
Compare BTX & SUPN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BTX
- SUPN
- Stock Information
- Founded
- BTX N/A
- SUPN 2005
- Country
- BTX United States
- SUPN United States
- Employees
- BTX N/A
- SUPN N/A
- Industry
- BTX
- SUPN Biotechnology: Pharmaceutical Preparations
- Sector
- BTX
- SUPN Health Care
- Exchange
- BTX Nasdaq
- SUPN Nasdaq
- Market Cap
- BTX 1.5B
- SUPN 1.8B
- IPO Year
- BTX N/A
- SUPN 2012
- Fundamental
- Price
- BTX $7.10
- SUPN $33.18
- Analyst Decision
- BTX
- SUPN Hold
- Analyst Count
- BTX 0
- SUPN 2
- Target Price
- BTX N/A
- SUPN $36.00
- AVG Volume (30 Days)
- BTX 777.3K
- SUPN 760.7K
- Earning Date
- BTX 08-15-2025
- SUPN 08-05-2025
- Dividend Yield
- BTX 14.30%
- SUPN N/A
- EPS Growth
- BTX N/A
- SUPN N/A
- EPS
- BTX N/A
- SUPN 1.11
- Revenue
- BTX N/A
- SUPN $667,997,000.00
- Revenue This Year
- BTX N/A
- SUPN N/A
- Revenue Next Year
- BTX N/A
- SUPN $12.02
- P/E Ratio
- BTX N/A
- SUPN $29.92
- Revenue Growth
- BTX N/A
- SUPN 11.82
- 52 Week Low
- BTX $5.10
- SUPN $27.05
- 52 Week High
- BTX $8.31
- SUPN $40.28
- Technical
- Relative Strength Index (RSI)
- BTX N/A
- SUPN 60.49
- Support Level
- BTX N/A
- SUPN $31.35
- Resistance Level
- BTX N/A
- SUPN $33.80
- Average True Range (ATR)
- BTX 0.00
- SUPN 0.92
- MACD
- BTX 0.00
- SUPN 0.16
- Stochastic Oscillator
- BTX 0.00
- SUPN 79.12
About BTX BlackRock Technology and Private Equity Term Trust Common Shares of Beneficial Interest
BlackRock Technology and Private Equity Term Trust objective is to provide total return and income through a combination of current income, current gains and long-term capital appreciation. The Trust will invest in equity securities issued by mid - and small capitalization companies that the Trust's adviser believes have above-average earnings growth potential.
About SUPN Supernus Pharmaceuticals Inc.
Supernus Pharmaceuticals Inc is a specialty pharmaceutical company. The company is engaged in developing and commercializing products for the treatment of central nervous system diseases, including neurological and psychiatric disorders. Its diverse neuroscience portfolio includes approved treatments for epilepsy, migraine, attention-deficit hyperactivity disorder (ADHD), hypomobility in Parkinson's Disease (PD), cervical dystonia, chronic sialorrhea, dyskinesia in PD patients receiving levodopa-based therapy, and drug-induced extrapyramidal reactions in adult patients. The company's products include Trokendi XR, Oxtellar XR, Qelbree, APOKYN, XADAGO, MYOBLOC, GOCOVRI, and Osmolex ER.